English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

This study investigated the effects of ponesimod, a selective S1P 1 receptor modulator, on T lymphocyte subsets in 16 healthy subjects. Lymphocyte subset proportions and absolute numbers were determined at baseline and on Day 10, after once-daily administration of ponesimod (10 mg, 20 mg, and 40 mg each consecutively for 3 days) or placebo (ratio 3:1). The overall change from baseline in lymphocyte count was -1,292±340×10 6 cells/L and 275±486×10 6 cells/L in ponesimod- and placebo-treated subjects, respectively. This included a decrease in both T and B lymphocytes following ponesimod treatment. A decrease in naïve CD4 + T cells (CD45RA + CCR7 + ) from baseline was observed only after ponesimod treatment (-113±98×10 6 cells/L, placebo: 0±18×10 6 cells/L). The number of T-cytotoxic (CD3 + CD8 + ) and T-helper (CD3 + CD4 + ) cells was significantly altered following ponesimod treatment compared with placebo. Furthermore, ponesimod treatment resulted in marked decreases in CD4 + T-central memory (CD45RA - CCR7 + ) cells (-437±164×10 6 cells/L) and CD4 + T-effector memory (CD45RA - CCR7 - ) cells (-131±57×10 6 cells/L). In addition, ponesimod treatment led to a decrease of -228±90×10 6 cells/L of gut-homing T cells (CLA - integrin β7 + ). In contrast, when compared with placebo, CD8 + T-effector memory and natural killer (NK) cells were not significantly reduced following multiple-dose administration of ponesimod. In summary, ponesimod treatment led to a marked reduction in overall T and B cells. Further investigations revealed that the number of CD4 + cells was dramatically reduced, whereas CD8 + and NK cells were less affected, allowing the body to preserve critical viral-clearing functions.

Effects of multiple-dose ponesimod, a selective S1P<sub>1</sub> receptor modulator, on lymphocyte subsets in healthy humans